Relay Therapeutics Soars 13.57% on Earnings Beat

Relay Therapeutics' stock surged 13.57% in pre-market trading on August 15, 2025, marking a significant rise that has caught the attention of investors and analysts alike.

Bank of America Securities recently issued a buy rating for Relay Therapeutics, reflecting a positive outlook on the company's prospects. This rating upgrade is driven by an upward trend in earnings estimates, which is a key factor influencing stock prices.

Relay Therapeutics has established itself as a pioneer in leveraging artificial intelligence for drug discovery, particularly in the field of oncology. This strategic focus has positioned the company at the forefront of innovative biotechnology solutions.

In the second quarter of 2025, Relay Therapeutics reported a 41% narrowing of its loss, surpassing analyst estimates for both GAAP revenue and earnings per share. The company's continued clinical advancements in its pipeline further bolster investor confidence.

JPMorgan analyst Eric Joseph lowered the price target for Relay Therapeutics to $11.00, while Raymond James Financial reduced its price objective from $29.00 to $19.00. These adjustments reflect the dynamic nature of market expectations and the company's performance.